Gregory A Daniels

5PUBLICATIONS
62CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes

|Nov 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez

|Oct 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.

Merve Hasanov, Denái R Milton, William H Sharfman

|Aug 31, 2021
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.

Robert H I Andtbacka, Brendan Curti, Gregory A Daniels

|Jul 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.

Adi Diab, Scott S Tykodi, Gregory A Daniels

Pageof 1

Frequent Collaborators

2 joint publications

Michele Maio

2 joint publications

Georgina V Long

2 joint publications

Mohammed Milhem

1 joint publications

Adi Diab